Repository logo
 
Publication

Multiple sclerosis patients treated with intramuscular IFN-β-1a autoinjector in a real-world setting: prospective evaluation of treatment persistence, adherence, quality of life and satisfaction.

2015Journal article Restricted access
Simple item page
dc.contributor.authorHupperts, R
dc.contributor.authorBecker, V
dc.contributor.authorFriedrich, J
dc.contributor.authorGobbi, C
dc.contributor.authorSalgado, AV
dc.contributor.authorSperling, B
dc.contributor.authorYou, X
dc.date.accessioned2016-05-05T14:06:22Z
dc.date.available2016-05-05T14:06:22Z
dc.date.issued2015
dc.description.abstractOBJECTIVES: The 12-month observational PERSIST study (NCT01405872) evaluated adherence associated with the intramuscular IFNβ-1a (i.m. IFN-β-1a) autoinjector pen in multiple sclerosis (MS) patients. METHODS: MS patients initiating i.m. IFN-β-1a autoinjector treatment were prospectively assessed for physician-reported persistence (percentage of patients remaining on therapy) and patient-reported outcomes, including adherence (percentage of unmissed injections), compliance (percentage of patients missing no injections), tolerability (injection-site reactions [ISRs] and pain) and satisfaction. RESULTS: The intent-to-treat population included 232 patients; of the 188 physician-reported 12-month completers, 182 patients remained on treatment (96.8% persistence). Monthly compliance rates were 87.5 - 96.2%. Mean monthly pain scores were 1.5 - 1.8 (scale: 0 = 'no pain'; 10 = 'extremely painful'). At 12 months, 73.5% of respondents reported no ISRs, 94.9% were satisfied/very satisfied with the autoinjector and 88.2% found using the device easy/very easy. Injection fear, injection anxiety and need for injection assistance by caregivers decreased from the initial visit to 12 months. No new safety signals were observed. CONCLUSIONS: The autoinjector pen is associated with high levels of persistence, compliance, adherence, and satisfaction, little-to-no pain and low need for caregiver assistance. Although these data are limited by reliance on patient questionnaires and the absence of a direct comparator group, this treatment may reduce barriers to injection therapy, while supporting long-term MS management.pt_PT
dc.identifier.citationExpert Opin Drug Deliv. 2015 Jan;12(1):15-25pt_PT
dc.identifier.doi10.1517/17425247.2015.989209pt_PT
dc.identifier.issn1744-7593
dc.identifier.urihttp://hdl.handle.net/10400.10/1631
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherInforma Healthcarept_PT
dc.subjectMultiple sclerosispt_PT
dc.subjectInterferon-betapt_PT
dc.subjectQuality of lifept_PT
dc.subjectMedication adherencept_PT
dc.titleMultiple sclerosis patients treated with intramuscular IFN-β-1a autoinjector in a real-world setting: prospective evaluation of treatment persistence, adherence, quality of life and satisfaction.pt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.conferencePlaceLondonpt_PT
oaire.citation.endPage25pt_PT
oaire.citation.startPage15pt_PT
oaire.citation.titleExpert opinion on drug deliverypt_PT
oaire.citation.volume12pt_PT
rcaap.rightsrestrictedAccess
rcaap.typearticlept_PT

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Expert Opin Drug Deliv. 2015 Jan, 12(1) 15-25.pdf
Size:
464.64 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

NEU - Artigos publicados em revistas não indexadas